Genentech is pulling Raptiva (efalizumab) from the market due to the risk of an opportunistic brain infection called PML
May 2009
Genentech is pulling Raptiva (efalizumab) from the market due to the risk of an opportunistic brain infection called PML.
PML (progressive multifocal leukoencephalopathy) is caused by a virus that attacks the brain when the immune system is severely weakened...usually due to AIDS, immunosuppressant therapy, etc.
Several long-term users of Raptiva have developed progressive multifocal leukoencephalopathy...most have died.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote